Bioactivation of Flutamide Metabolites by Human Liver Microsomes

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1425-1437

  Kang, Ping ^a   Dalvie, Deepak ^a   Smith, Evan ^a   Zhou, Sue ^a   Deese, Alan ^a,b   Nieman, James A ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYFLUTAMIDE; 4 NITRO 3 (TRIFLUOROMETHYL)PHENYLAMINE; ANTIANDROGEN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DRUG METABOLITE; FLUTAMIDE; GLUTATHIONE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; FIRST PASS EFFECT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; LIVER TOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; TANDEM MASS SPECTROMETRY;

ANDROGEN ANTAGONISTS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FLUTAMIDE; GLUTATHIONE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSOMES, LIVER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 46449105732     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020370     Document Type: Article

References (33)

1. Aizawa Y, Ikemoto I, Kishimoto K, Wada T, Yamazaki H, Ohishi Y, Kiyota H, Furuta N, Suzuki H, and Ueda M (2003) Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. Mol Cell Biochem 252:149-156.
2. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, Beaune P, Pompon D, et al. (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450 including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 265:366-372.
3. Brogden RN and Clissold SP (1989) Flutamide: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. Drugs 38:185-203.
4. Cetin M, Demirci D, Unal A, Altinbas M, Guven M, Unluhizarci K (1999) Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 18:137-140.
5. Dean JA (1987) Handbook of Organic Chemistry. McGraw-Hill, New York.
6. 13C]-dimethyl-p-benzoquinonediimine. Chem Res Toxicol 19:1248-1256.
7. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, and Pessayre D (1994) Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962.
8. Gallemann D and Eyer P (1994) Additional pathways of S-conjugate formation during the interaction of thiols with nitrosoarenes bearing pi-donating substituents. Environ Health Perspect 102:137-142.
9. Gallemann D, Greif A, Eyer P, Dasenbrock J, Wimmer E, Sonnenbichler J, Sonnenbichler I, Schafer W, Buhrow I (1998a) Formation of 4,4-dialkoxycyclohexa- 2,5-dienone N-(thiol-S-yl)imine during reaction of 4-alkoxynitrosobenzenes with thiols in alcoholic solvents. Chem Res Toxicol 11:1423-1433.
10. Gallemann D, Greif A, Eyer P, Wagner HU, Sonnenbichler J, Sonnenbichler I, Schafer W, Buhrow I (1998b) Additional pathways of S-conjugate formation during interaction of 4-nitrosophenetole with glutathione. Chem Res Toxicol 11:1411-1422.
11. Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y, Nagata K, and Yamazoe Y (2006) Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos 34:828-835.
12. Gomez JL, Dupont A, Cusan L, Tremblay M, Tremblay M, and Labrie F (1992) Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. Am J Med 92:563-566.
13. Hart W and Stricker BHC (1989) Flutamide and hepatitis. Ann Intern Med 110:943-944.
14. Ichimura E, Hara K, Matsuzaki Y, and Doi M (1999) Improvement of flutamide-induced hepatotoxicity by ursodeoxycholic acid in male rats. Acta Hepatol Jpn 40:227-234.
15. Kang P, Dalvie D, Smith E, Zhou S, Deese A (2007) Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos 35:1081-1088.
16. Katchen B and Buxbaum S (1975) Disposition of a new, nonsteroid, antiandrogen, alpha, alpha, alpha-trifluoro-2-methyl-4′-nitro-m- propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 41:373-379.
17. Kazanis S and McClelland RA (1992) Electrophilic intermediate in the reaction of glutathione and nitrosoarenes. J Am Chem Soc 114:3052-3059.
18. Kostrubsky SE, Strom SC, Ellis E, Nelson SD, Mutlib AE (2007) Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites. Chem Res Toxicol 20:1503-1512.
19. Matsuzaki Y, Nagai D, Ichimura E, Goda R, Tomura A, and Doi M (2006) Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J Gastroenterol 41:231-239.
20. McLeod DG (1993) Antiandrogenic drugs. Cancer 71:1046-1049.
21. Nakagawa Y, Koyama M, and Matsumoto M (1999) Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer. Acta Urol Jpn 45:821-826.
22. Ortiz de Montellano PR (1995) Substrate oxidation by cytochrome P450 enzymes, in Cytochrome P450: structure, mechanism and biochemistry (Ortiz de Montellano PR eds) pp. 274-276, Plenum Press, New York.
23. Osculati A and Castiglioni C (2006) Fatal liver complications with flutamide. Lancet 367:1140-1141.
24. Ozono S, Yamaguchi A, Mochizuki H, Kawakami T, Fujimoto K, Otani T, Yoshida K, Ichinei M, Yamashita T, Hirao Y (2002) Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis 5:128-131.
25. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
26. Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T, Jr., Lin JS, Hagman WK, Evans DC, et al. (2003) Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling technique. J Mass Spectrom 38:211-221.
27. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, and Bennett CL (2001) Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57:727-732.
28. Soglia JR, Contillo LG, Kalgutkar AS, Zhao S, Hop CE, Boyd JG, and Cole MJ (2006) A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. Chem Res Toxicol 19:480-490.
29. Straube E, Volkel W, Bringmann G, Dekant W (2005) Reaction of nitroso derivatives of dinitropyrenes with sulfhydryl groups of peptides and hemoglobin in vitro and in rats. Xenobiotica 35:1147-1164.
30. Takashima E, Iguchi K, Usui S, Yamamoto H, Hirano K (2003) Metabolite profiles of flutamide in serum from patients with flutamide-induced hepatic dysfunction. Biol Pharm Bull 26:1455-1460.
31. Tevell A, Lennernas H, Jonsson M, Norlin M, Lennernas B, Bondesson U, and Hedeland M (2006) Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectometry. Drug Metab Dispos 34:984-992.
32. Thole Z, Manso G, Salgueiro E, Revuelta P, and Hidalgo A (2004) Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 73:289-295.
33. Wysowski DK and Fourcroy JL (1996) Flutamide hepatotoxicity. J Urol 155:209-212.